SS
LPCN icon

SBI Securities’s Lipocine LPCN Stock Holding History

SBI Securities’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172 Hold
67
– – ﹤0.01% 3367
2026
Q1 		$535 Hold
67
– – ﹤0.01% 2875
2025
Q4 		$538 Hold
67
– – ﹤0.01% 2848
2025
Q3 		$191 Hold
67
– – ﹤0.01% 3331
2025
Q2 		$212 Hold
67
– – ﹤0.01% 3287
2025
Q1 		$213 Buy
+67
New +$259 ﹤0.01% 3208

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SBI Securities's LPCN Position: Q2 2026 in Review

SBI Securities held its Lipocine (LPCN) position steady in Q2 2026 at 67 shares worth $172. The position accounts for ﹤0.01% of the portfolio, ranked #3367.

SBI Securities first reported a position in LPCN in Q1 2025 and has held it in 6 quarters since. The position peaked at $538 in Q4 2025. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • SBI Securities held 67 shares of Lipocine worth $172 as of Q2 2026.
  • SBI Securities left its Lipocine share count unchanged in Q2 2026.
  • Lipocine made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3367 holding.
  • SBI Securities first reported a position in Lipocine in Q1 2025 and has held it in 6 quarters since.
  • SBI Securities's Lipocine position peaked at $538 in Q4 2025.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.